This TGFBR2-driven ITL gene signature had a significantly higher expression in patient GSCs compared to all neoplastic GBM cells within patient tumors (Figure 3J), emphasizing the enrichment of this signature in stem-like cells. The gene discussed is TGFBR2; the disease is glioblastoma.